A combination of the Lactobacillus rhamnosus GR-1® and Lactobacillus reuteri RC-14® (hereafter referred to by use of the trademarks, GR-1® and RC-14®), the UREX™ strain combination has been associated with support of the female urogenital tracts of teens, premenopausal and post-menopausal women.
The UREX™ combination is the worlds most documented probiotics for women’s urogenital health.
How Chr. Hansen created UREX™
The Lactobacillus rhamnosus GR-1® strain was isolated in 1980 from distal urethra of a healthy woman while the Lactobacillus reuteri, RC-14® strain was isolated in 1985 from the vagina of a healthy woman.
The strains have since been vigorously investigated in studies ranging from lab studies to randomized double-blinded, placebo-controlled trials. The first trial on the GR-1® strain was published in 1988, and the first trial on the RC-14® strain published in 2001. More than 30 trials have been published using the GR-1® and RC-14® strains in combination.
The UREX™ strain combination helps provide relief from bacterial imbalances in the urogenital tracts
The UREX™ strain combination has been associated with beneficial effects across the female urogenital tracts in both teens, premenopausal and post-menopausal women. The UREX™ combination has been shown that it:
- may provide relief from vaginal bacterial imbalance alone and in combination with standard health care intervention1-6
- may help establish and maintain a healthy vaginal pH3
- may help support a healthy vaginal microbiota following vaginal bacterial imbalance4
- support balancing of the vaginal microbiota during challenges with yeast overgrowth8
- may reduce vaginal discharge8
- may increase the abundance of healthy lactobacilli in the vaginal tract9, 2
- may reduce the number of times with challenges due to bacterial imbalance in the urinary tract.7
Full control of all manufacturing steps so UREX™ is safe and of high quality
Chr. Hansen has a unique manufacturing process with full control of all steps during the production of our probiotic strains. This results in high quality probiotic strains with superior quality and safety.
In Europe, Lactobacillus rhamnosus and Lactobacillus reuteri has been granted Qualified Presumption of Safety (QPS) status by the European Food Safety Authority (EFSA) – a status granted on species level.
The UREX™ strains have been provided to girls, teens, premenopausal and postmenopausal women and pregnant women without safety issues.
How UREX™ works
The UREX™ strains may alleviate bacterial imbalance e.g. by producing antimicrobial substances. The UREX™ strains help lower vaginal PH by producing lactic acid. And the UREX™ strains help reduce harmful biofilms.
1 Petricevic et al, European Journal of Obstetrics Gynecology and Reproductive Biology, 2008; 141(1):54–57.
2 Anukam et al, Microbes and Infection, 2006; 8(12–13):2772–2776.
3 Martinez et al, Canadian Journal of Microbiology, 2009; 55(2):133–138.
4 Vujic et al, European Journal of Obstetrics Gynecology and Reproductive Biology, 2013; 168(1):75–79.
5 Reid et al, FEMS Immunology and Medical Microbiology, 2003; 35(2):131–134.
6 Reid et al, Journal of Medicinal Food, 2004; 7(2):223–228.
7 Beerepoot et al, Archives of Internal Medicine, 2012; 172(9):704–712.
8 Martinez et al, Letters in Applied Microbiology, 2009; 48(3):269–274.
9 Macklaim et al. Microbial ecology in health and disease, 2015; 26:27799
10 Morelli et al. J Clin Gastroenterol, 2004, 38, 107-110.
GR-1®, RC-14® and UREX™ are trademarks of Chr. Hansen A/S.
This communication is only intended for business-to-business and health care professionals. This communication is not intended for consumers of final consumer goods. Nothing on this page is meant to be perceived as an approved claim.